O	0	11	Preliminary
O	12	19	results
O	20	22	on
O	23	29	safety
O	30	33	and
O	34	42	activity
O	43	45	of
O	46	47	a
O	48	58	randomized
O	58	59	,
O	60	66	double
O	66	67	-
O	67	72	blind
O	72	73	,
O	74	75	2
O	76	77	x
O	78	79	2
O	80	85	trial
O	86	88	of
B-intervention	89	92	low
I-intervention	92	93	-
I-intervention	93	97	dose
I-intervention	98	107	tamoxifen
I-intervention	108	111	and
I-intervention	112	123	fenretinide
O	124	127	for
O	128	134	breast
O	135	141	cancer
O	142	152	prevention
O	153	155	in
O	156	169	premenopausal
O	170	175	women
O	175	176	.

O	177	179	To
O	180	189	determine
O	190	197	whether
O	198	201	low
O	201	202	-
O	202	206	dose
O	207	216	tamoxifen
O	217	220	and
O	221	232	fenretinide
O	233	237	have
O	238	239	a
O	240	251	synergistic
O	252	258	effect
O	259	261	on
O	262	271	surrogate
O	272	282	biomarkers
O	282	283	,
O	284	293	including
O	294	305	circulating
O	306	313	insulin
O	313	314	-
O	314	318	like
O	319	325	growth
O	326	332	factor
O	333	334	I
O	335	336	(
O	336	339	IGF
O	339	340	-
O	340	341	I
O	341	342	)
O	343	346	and
O	347	359	mammographic
O	360	367	density
O	367	368	,
O	369	371	in
B-eligibility	372	385	premenopausal
I-eligibility	386	391	women
I-eligibility	392	394	at
I-eligibility	395	399	risk
I-eligibility	400	403	for
I-eligibility	404	410	breast
I-eligibility	411	417	cancer
O	418	421	and
O	422	424	to
O	425	430	study
O	431	435	drug
O	436	442	safety
O	442	443	.

O	444	457	Premenopausal
O	458	463	women
O	464	465	(
O	465	466	n
O	467	468	=
B-total-participants	469	472	235
O	472	473	)
O	474	478	were
O	479	487	randomly
O	488	496	assigned
O	497	499	in
O	500	501	a
O	502	508	double
O	508	509	-
O	509	514	blind
O	515	519	four
O	519	520	-
O	520	523	arm
O	524	529	trial
O	530	532	to
O	533	540	receive
O	541	550	tamoxifen
O	551	552	5
O	553	555	mg
O	555	556	/
O	556	557	d
O	557	558	,
O	559	570	fenretinide
O	571	574	200
O	575	577	mg
O	577	578	/
O	578	579	d
O	579	580	,
O	581	585	both
O	586	592	agents
O	592	593	,
O	594	596	or
B-control	597	604	placebo
O	605	608	for
O	609	610	2
O	611	616	years
O	616	617	.

O	618	621	The
O	622	629	present
O	630	638	analysis
O	639	645	refers
O	646	648	to
O	649	660	preliminary
O	661	665	data
O	666	668	on
O	669	675	safety
O	675	676	,
O	677	680	IGF
O	680	681	-
O	681	682	I
O	682	683	,
O	684	687	and
O	688	694	breast
O	695	701	cancer
O	702	708	events
O	708	709	.

O	710	718	Patients
O	719	723	were
O	724	732	included
O	733	735	if
O	736	740	they
O	741	744	had
O	745	747	an
O	748	755	excised
O	756	762	ductal
O	763	772	carcinoma
O	772	773	-
O	773	775	in
O	775	776	-
O	776	780	situ
O	781	782	(
O	782	784	57
O	784	785	%
O	785	786	)
O	786	787	,
O	788	795	lobular
O	796	805	carcinoma
O	805	806	-
O	806	808	in
O	808	809	-
O	809	813	situ
O	814	815	(
O	815	817	13
O	817	818	%
O	818	819	)
O	819	820	,
O	821	828	minimal
O	829	837	invasive
O	838	844	breast
O	845	851	cancer
O	852	853	(
O	853	854	7
O	854	855	%
O	855	856	)
O	856	857	,
O	858	860	or
O	861	862	a
O	863	864	5
O	864	865	-
O	865	869	year
O	870	874	Gail
O	875	879	risk
O	880	881	>
O	882	884	or
O	885	886	=
O	887	888	1
O	888	889	.
O	889	890	3
O	890	891	%
O	892	893	(
O	893	895	23
O	895	896	%
O	896	897	)
O	897	898	.

O	899	904	After
O	905	906	a
O	907	913	median
O	914	920	follow
O	920	921	-
O	921	923	up
O	924	926	of
O	927	929	40
O	930	936	months
O	936	937	,
O	938	943	there
O	944	947	was
O	948	949	a
O	950	959	reduction
O	960	962	of
O	963	965	13
O	965	966	%
O	966	967	,
O	968	969	2
O	969	970	%
O	970	971	,
O	972	974	20
O	974	975	%
O	975	976	,
O	977	980	and
O	981	982	1
O	982	983	%
O	984	986	in
B-outcome	987	990	IGF
I-outcome	990	991	-
I-outcome	991	992	I
I-outcome	993	999	levels
O	1000	1003	for
O	1004	1012	patients
O	1013	1015	on
O	1016	1025	tamoxifen
O	1025	1026	,
O	1027	1038	fenretinide
O	1038	1039	,
O	1040	1049	tamoxifen
O	1050	1054	plus
O	1055	1066	fenretinide
O	1066	1067	,
O	1068	1071	and
O	1072	1079	placebo
O	1079	1080	,
O	1081	1093	respectively
O	1093	1094	.

O	1095	1106	Recruitment
O	1107	1110	was
O	1111	1118	stopped
O	1119	1124	based
O	1125	1127	on
O	1128	1131	the
O	1132	1136	lack
O	1137	1139	of
O	1140	1142	an
O	1143	1154	interaction
O	1155	1157	on
B-outcome-Measure	1158	1161	IGF
I-outcome-Measure	1161	1162	-
I-outcome-Measure	1162	1163	I
I-outcome-Measure	1164	1170	levels
O	1170	1171	,
O	1172	1177	which
O	1178	1181	was
O	1182	1183	a
O	1184	1191	primary
O	1192	1195	end
O	1196	1201	point
O	1202	1205	for
O	1206	1209	the
O	1210	1215	study
O	1215	1216	.

O	1217	1223	Thirty
O	1223	1224	-
O	1224	1227	six
O	1228	1236	patients
O	1237	1241	have
B-outcome	1242	1249	dropped
I-outcome	1250	1253	out
O	1254	1256	of
O	1257	1260	the
O	1261	1266	study
O	1266	1267	,
O	1268	1270	17
O	1271	1278	because
O	1279	1281	of
B-outcome	1282	1289	adverse
I-outcome	1290	1296	events
O	1297	1300	and
O	1301	1303	19
O	1304	1307	for
O	1308	1315	various
B-outcome	1316	1321	other
I-outcome	1322	1329	reasons
O	1329	1330	.

B-iv-bin-abs	1331	1334	One
O	1335	1340	stage
O	1341	1342	I
O	1343	1354	endometrial
O	1355	1361	cancer
O	1362	1370	occurred
O	1371	1373	in
O	1374	1375	a
O	1376	1383	patient
O	1384	1386	on
O	1387	1398	fenretinide
O	1398	1399	,
O	1400	1403	and
B-iv-bin-abs	1404	1407	one
B-outcome	1408	1413	optic
I-outcome	1414	1419	nerve
I-outcome	1420	1428	ischemia
O	1429	1432	and
B-iv-bin-abs	1433	1436	one
B-outcome	1437	1441	deep
I-outcome	1442	1448	venous
I-outcome	1449	1459	thrombosis
O	1460	1468	occurred
O	1469	1471	on
O	1472	1481	tamoxifen
O	1481	1482	.

O	1483	1488	There
O	1489	1492	was
O	1493	1495	no
O	1496	1506	difference
O	1507	1509	in
B-outcome	1510	1520	menopausal
I-outcome	1521	1529	symptoms
O	1529	1530	,
B-outcome	1531	1542	endometrial
I-outcome	1543	1552	thickness
O	1552	1553	,
B-outcome	1554	1560	polyps
O	1560	1561	,
O	1562	1564	or
B-outcome	1565	1572	ovarian
I-outcome	1573	1578	cysts
O	1579	1584	among
O	1585	1594	treatment
O	1595	1599	arms
O	1599	1600	.

O	1601	1603	To
O	1604	1608	date
O	1608	1609	,
O	1610	1612	24
B-outcome	1613	1619	breast
I-outcome	1620	1627	cancers
O	1628	1632	have
O	1633	1637	been
O	1638	1646	observed
O	1646	1647	,
O	1648	1655	without
O	1656	1667	differences
O	1668	1673	among
O	1674	1678	arms
O	1678	1679	.

O	1680	1683	The
O	1684	1695	combination
O	1696	1698	of
O	1699	1702	low
O	1702	1703	-
O	1703	1707	dose
O	1708	1717	tamoxifen
O	1718	1721	and
O	1722	1733	fenretinide
O	1734	1736	is
O	1737	1741	safe
O	1742	1745	but
O	1746	1749	not
O	1750	1761	synergistic
O	1762	1764	in
O	1765	1773	lowering
O	1774	1777	IGF
O	1777	1778	-
O	1778	1779	I
O	1780	1786	levels
O	1787	1789	in
O	1790	1803	premenopausal
O	1804	1809	women
O	1809	1810	.

O	1811	1814	The
O	1815	1823	clinical
O	1824	1836	implications
O	1837	1844	require
O	1845	1852	further
O	1853	1859	follow
O	1859	1860	-
O	1860	1862	up
O	1862	1863	.
